Trevena, Inc. (TRVN)
NASDAQ: TRVN · IEX Real-Time Price · USD
0.396
-0.004 (-1.03%)
May 1, 2024, 12:09 PM EDT - Market open
Trevena Revenue
In the year 2023, Trevena had annual revenue of $3.13M, a decrease of -847.61%. Revenue in the quarter ending December 31, 2023 was $-82.00K.
Revenue (ttm)
$3.13M
Revenue Growth
-847.61%
P/S Ratio
1.94
Revenue / Employee
$135,870
Employees
23
Market Cap
6.01M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.13M | 3.54M | -847.61% |
Dec 31, 2022 | -418.00K | -985.00K | -173.72% |
Dec 31, 2021 | 567.00K | -2.50M | -81.52% |
Dec 31, 2020 | 3.07M | 3.04M | 9,800.00% |
Dec 31, 2019 | 31.00K | -5.70M | -99.46% |
Dec 31, 2018 | 5.73M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 3.75M | -2.50M | -40.00% |
Dec 31, 2015 | 6.25M | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 134.98K | -672.62K | -83.29% |
Dec 31, 2012 | 807.60K | -1.61M | -66.65% |
Dec 31, 2011 | 2.42M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ThermoGenesis Holdings | 9.45M |
Xenetic Biosciences | 2.54M |
Soligenix | 839.36K |
Mangoceuticals | 731.49K |
Creative Medical Technology Holdings | 9.00K |
TRVN News
- 4 weeks ago - Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise - GlobeNewsWire
- 4 months ago - Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise - GlobeNewsWire
- 5 months ago - Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting - GlobeNewsWire
- 5 months ago - Trevena Awarded OLINVYK Agreement with Premier, Inc. - GlobeNewsWire
- 5 months ago - Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries - GlobeNewsWire
- 6 months ago - Trevena Reports Third Quarter 2023 Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023 - GlobeNewsWire